CorMedix Inc (CRMD) - Total Assets
Based on the latest financial reports, CorMedix Inc (CRMD) holds total assets worth $750.86 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CorMedix Inc shareholders equity for net asset value and shareholders' equity analysis.
CorMedix Inc - Total Assets Trend (2008–2024)
This chart illustrates how CorMedix Inc's total assets have evolved over time, based on quarterly financial data.
CorMedix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
CorMedix Inc's total assets of $750.86 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.2% |
| Accounts Receivable | $51.65 Million | 43.5% |
| Inventory | $7.60 Million | 6.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.84 Million | 1.6% |
| Goodwill | $1.84 Billion | 1550.2% |
Asset Composition Trend (2008–2024)
This chart illustrates how CorMedix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CorMedix Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CorMedix Inc's current assets represent 96.4% of total assets in 2024, an increase from 85.5% in 2008.
- Cash Position: Cash and equivalents constituted 34.2% of total assets in 2024, down from 85.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1551.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 1550.2% of total assets.
CorMedix Inc Competitors by Total Assets
Key competitors of CorMedix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
CorMedix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.94 | 3.96 | 11.58 |
| Quick Ratio | 1.73 | 3.60 | 11.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $125.89 Million | $54.67 Million | $44.02 Million |
CorMedix Inc - Advanced Valuation Insights
This section examines the relationship between CorMedix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.62 |
| Latest Market Cap to Assets Ratio | 5.03 |
| Asset Growth Rate (YoY) | 44.8% |
| Total Assets | $118.85 Million |
| Market Capitalization | $597.22 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values CorMedix Inc's assets at a significant premium (5.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: CorMedix Inc's assets grew by 44.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CorMedix Inc (2008–2024)
The table below shows the annual total assets of CorMedix Inc from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $118.85 Million | +44.83% |
| 2023-12-31 | $82.06 Million | +32.27% |
| 2022-12-31 | $62.04 Million | -10.02% |
| 2021-12-31 | $68.95 Million | +39.83% |
| 2020-12-31 | $49.31 Million | +67.28% |
| 2019-12-31 | $29.48 Million | +56.57% |
| 2018-12-31 | $18.83 Million | +39.93% |
| 2017-12-31 | $13.45 Million | -38.58% |
| 2016-12-31 | $21.91 Million | -40.96% |
| 2015-12-31 | $37.10 Million | +627.80% |
| 2014-12-31 | $5.10 Million | +71.77% |
| 2013-12-31 | $2.97 Million | +157.34% |
| 2012-12-31 | $1.15 Million | -54.88% |
| 2011-12-31 | $2.56 Million | -71.11% |
| 2010-12-31 | $8.85 Million | +297.54% |
| 2009-12-31 | $2.23 Million | +37.36% |
| 2008-12-31 | $1.62 Million | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Pict… Read more